Dominated by T-cell checkpoint inhibitor and chimeric antigen receptor (CAR) T-cell therapies, cancer immunotherapy has achieved remarkable clinical efficacy in patients with different types of cancer, including GC12–15. This evidence concerns the gene TBXT and cancer.